EGF receptor family: twisting targets for improved cancer therapies

References

• Alvarado D, Klein DE, Lemmon MA. 2010. Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Cell 142:568–579
   PubMed Web of Science ®Google Scholar
• Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, Wemmer DE, Kuriyan J, et al. 2013. Architecture and membrane interactions of the EGF receptor. Cell 152:557–569
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. 2012. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nature Rev Clin Oncol 9:16–32
   PubMed Web of Science ®Google Scholar
• Bagchi A, Bessman NJ, Wu NZ, Raines L, Kan Z, Hu W, Englander W, et al. 2014. Allosteric regulation of the epidermal growth factor receptor. Biophys J 106:105a
   Google Scholar
• Ben-Chetrit N, Tarcic G, Yarden Y. 2013. ERK-ERF-EGR1, a novel switch underlying acquisition of a motile phenotype. Cell Adh Migr 7:33–37
   PubMed Web of Science ®Google Scholar
• Blair BG, Bardelli A, Park BH. 2014. Somatic alterations as the basis for resistance to targeted therapies. J Pathol 232:244–254
   PubMed Web of Science ®Google Scholar
• Blümer J, Rey J, Dehmelt L, Mazel T, Wu YW, Bastiaens P, Goody RS, et al. 2013. RabGEFs are a major determinant for specific Rab membrane targeting. J Cell Biol 200:287–300
   PubMed Web of Science ®Google Scholar
• Chung I, Reichelt M, Dowbenko D, Mellman I, Sliwkowski M. 2014. HER2 overexpression induces membrane deformation that increases cell motility. Biophys J 106:523a
   Google Scholar
• Coskun Ü, Grzybek M, Drechsel D, Simons K. 2011. Regulation of human EGF receptor by lipids. Proc Natl Acad Sci 108:9044–9048
   Google Scholar
• Cutler PJ, Malik MD, Liu S, Byars JM, Lidke DS, Lidke KA. 2013. Multi-color quantum dot tracking using a high-speed hyperspectral line-scanning microscope. PLoS One 8:e64320
   Google Scholar
• DiGiulio S. 2013. FDA approves Kadcyla (T-DM1) for late-stage breast cancer. Oncology Times 35:21
   Google Scholar
• Ehrlich M, Horbelt D, Marom B, Knauz P, Henis YI. 2011. Homomeric and heteromeric complexes among TGF-β and BMP receptors and their roles in signaling. Cell Signal 23:1424–1432
   Google Scholar
• Endres NF, Das R, Smith AW, Arkhipov A, Kovacs E, Huang Y, Pelton JG, et al. 2013. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152:543–556
   PubMed Web of Science ®Google Scholar
• Faigenbaum R, Haklai R, Ben-Baruch G, Kloog Y. 2013. Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. Oncotarget 4:316–328
   Google Scholar
• Fortian A, Sorkin A. 2014. Live-cell fluorescence imaging reveals high stoichiometry of Grb2 binding to the EGF receptor sustained during endocytosis. J Cell Sci 127:432–444
   PubMed Web of Science ®Google Scholar
• Gan HK, Burgess AW, Clayton AH, Scott AM. 2012. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 72:2924–2930
   PubMed Web of Science ®Google Scholar
• Haenzi B, Bonny O, Masson R, Lienhard S, Dey JH, Kuro-o M, Hynes NE. 2014. Loss of Memo, a novel FGFR regulator, results in reduced lifespan. FASEB J 28:327–336
   Google Scholar
• Hirokawa Y, Yip K, Tan CW, Burgess AW. 2014. Colonic myofibroblast cell line stimulates colonoid formation. Am J Physiol Gastrointestinal Liver Physiol. [Epub ahead of print]. doi: 10.1152/ajpgi.00267.2013
   Google Scholar
• Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, Faratian D. 2013. Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer. Cellular Signal 25:26–32
   PubMed Web of Science ®Google Scholar
• Huang F, Zeng X, Kim W, Balasubramani M, Fortian A, Gygi SP, Yates NA, et al. 2013. Lysine 63-linked polyubiquitination is required for EGF receptor degradation. Proc Natl Acad Sci U S A 110:15722–15727
   PubMed Web of Science ®Google Scholar
• Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, et al. 2013. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23:603–617
   PubMed Web of Science ®Google Scholar
• Jiang K, Yang Z, Cheng L, Wang S, Ning K, Zhou L, Lin J, et al. 2013. Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2. J Biolog Chem 288:24590–24599
   Google Scholar
• Johns TG, McKay MJ, Cvrljevic AN, Gan HK, Taylor C, Xu H, Smyth FE, et al. 2010. MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2–7 epidermal growth factor receptor. Int J Radiation Oncol* Biol* Phys 78:572–578
   PubMed Web of Science ®Google Scholar
• Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Plückthun A. 2013. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure 21:1979–1991
   Google Scholar
• Kamath AV, Lu D, Gupta P, Jin D, Xiang H, Wong A, Leddy C, et al. 2012. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 69:1063–1069
   PubMed Web of Science ®Google Scholar
• Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D, Yan Y, et al. 2013. Network quantification of EGFR signaling unveils potential for targeted combination therapy. Molec Syst Biol 9:673
   Google Scholar
• Kozer N, Barua D, Orchard S, Nice EC, Burgess AW, Hlavacek WS, Clayton AH. 2013. Exploring higher-order EGFR oligomerisation and phosphorylation – A combined experimental and theoretical approach. Molec BioSystems 9:1849–1863
   Google Scholar
• Leahy DJ. 2013. Piecing together the extracellular puzzle. Cell 154:23–25
   Google Scholar
• Lee FT, O'Keefe GJ, Gan HK, Mountain AJ, Jones GR, Saunder TH, Sagona J, et al. 2010. Immuno-PET quantitation of de2–7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4–labeled antibody ch806. J Nucl Med 51:967–972
   PubMedGoogle Scholar
• Liu P, Cleveland TE, Bouyain S, Byrne PO, Longo PA, Leahy DJ. 2012. A single ligand is sufficient to activate EGFR dimers. Proc Natl Acad Sci 109:10861–10866
   PubMed Web of Science ®Google Scholar
• Lorenz S, Cantor AJ, Rape M, Kuriyan J. 2013. Macromolecular juggling by ubiquitylation enzymes. BMC Biol 11:65
   Google Scholar
• Makki N, Thiel KW, Miller FJ. 2013. The epidermal growth factor receptor and its ligands in cardiovascular disease. Intl J Molec Sci 14:20597–20613
   PubMed Web of Science ®Google Scholar
• Marone R, Hess D, Dankort D, Muller WJ, Hynes NE, Badache A. 2004. Memo mediates ErbB2-driven cell motility. Nature Cell Biol 6:515–522
   PubMedGoogle Scholar
• Mellman I, Yarden Y. 2013. Endocytosis and cancer. Cold Spring Harb Perspect Biol 5:a016949
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. 2013. Personalizing oncology: Perspectives and prospects. J Clin Oncol 31:1904–1911
   PubMed Web of Science ®Google Scholar
• Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, et al. 2013. Abstract C94: Heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer are sensitive to concomitant inhibition of EGFR and MEK. Molec Cancer Ther 12:C94–C94
   Google Scholar
• Needham SR, Hirsch M, Rolfe DJ, Clarke DT, Zanetti-Domingues LC, Wareham R, Martin-Fernandez ML. 2013. Measuring EGFR separations on cells with ∼10 nm resolution via fluorophore localization imaging with photobleaching. PLoS One 8:e62331
   Google Scholar
• Nguyen LK, Kolch W, Kholodenko BN. 2013. When ubiquitination meets phosphorylation: A systems biology perspective of EGFR/MAPK signalling. Cell Commun Signal 11:52
   PubMed Web of Science ®Google Scholar
• Phillips GDL, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, et al. 2014. Dual Targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: Critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 20:456–468
   PubMed Web of Science ®Google Scholar
• Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, et al. 2012. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 149:146–158
   PubMed Web of Science ®Google Scholar
• Rolfe DJ, McLachlan CI, Hirsch M, Needham SR, Tynan CJ, Webb SE, Martin-Fernandez ML, et al. 2011. Automated multidimensional single molecule fluorescence microscopy feature detection and tracking. Eur Biophys J 40:1167–1186
   Google Scholar
• Schlatter ID, Meira M, Ueberschlag V, Hoepfner D, Movva R, Hynes NE. 2012. MHO1, an evolutionarily conserved gene, is synthetic lethal with PLC1; Mho1p has a role in invasive growth. PLoS One 7:e32501
   Google Scholar
• Schmitz KR, Bagchi A, Roovers RC, van Bergen en Henegouwen PM, Ferguson KM. 2013. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure 21:1214–1224
   PubMed Web of Science ®Google Scholar
• Schokoroy S, Juster D, Kloog Y, Pinkas-Kramarski R. 2013. Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death. PLoS One 8:e75269
   Google Scholar
• Schreier B, Rabe S, Schneider B, Bretschneider M, Rupp S, Ruhs S, Neumann J, et al. 2013. Loss of epidermal growth factor receptor in vascular smooth muscle cells and cardiomyocytes causes arterial hypotension and cardiac hypertrophy. Hypertension 61:333–340
   Google Scholar
• Sezgin E, Levental I, Grzybek M, Schwarzmann G, Mueller V, Honigmann A, Belov VN, et al. 2012. Partitioning, diffusion, and ligand binding of raft lipid analogs in model and cellular plasma membranes. Biochim Biophys Acta 1818:1777–1784
   Google Scholar
• Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, Du Y, et al. 2013. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497:383–387
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX. 2012. Pari passu dimers of dimers. Proc Natl Acad Sci USA 109:13140–13141
   PubMedGoogle Scholar
• Sorkin A, Puthenveedu MA. 2013. Clathrin-mediated endocytosis. In: Yarden Y, Tarcic G, Editors. Vesicle Trafficking in Cancer. New York: Springer
   Google Scholar
• Tan CW, Hirokawa Y, Gardiner BS, Smith DW, Burgess AW. 2013. Colon cryptogenesis: Asymmetric budding. PLoS One 8:e78519
   Google Scholar
• Valley CC, Lidke KA, Lidke DS. 2013. The spatiotemporal organization of ErbB receptors: Insights from microscopy. Cold Spring Harbor Perspect Biol 6:a020735
   Google Scholar
• Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, et al. 2013. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Intl J Cancer 133:1259–1265
   PubMed Web of Science ®Google Scholar
• Vosjan MJ, Perk LR, Roovers RC, Visser GW, Stigter-van Walsum M, van Bergen en Henegouwen PM, van Dongen GA. 2011. Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Molec Imaging 38:753–763
   PubMed Web of Science ®Google Scholar
• Wagner JP, Wolf-Yadlin A, Sevecka M, Grenier JK, Root DE, Lauffenburger DA, MacBeath G. 2013. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks. Science Signal 6:ra58 (1–17)
   Google Scholar
• Walker F, Rothacker J, Henderson C, Nice EC, Catimel B, Zhang HH, Scott AM, et al. 2012. Ligand binding induces a conformational change in epidermal growth factor receptor dimers. Growth Factors 30:394–409
   Web of Science ®Google Scholar
• Wang Y, Poulin E, Coffey R. 2013. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Brit J Cancer 108:1765–1770
   PubMed Web of Science ®Google Scholar
• Whatcott C, Han H, Posner RG, Von Hoff DD. 2013. Tumor-stromal interactions in pancreatic cancer. Crit Reviews™ Oncogenesis 18:135–151
   PubMedGoogle Scholar
• Zigler M, Shir A, Levitzki A. 2013. Targeted cancer immunotherapy. Curr Opinion Pharmacol 13:504–510
   Google Scholar
• Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, Hahn SA, et al. 2013. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 497:638–642
   PubMed Web of Science ®Google Scholar
• Ziomkiewicz I, Loman A, Klement R, Fritsch C, Klymchenko AS, Bunt G, Jovin TM, et al. 2013. Dynamic conformational transitions of the EGF receptor in living mammalian cells determined by FRET and fluorescence lifetime imaging microscopy. Cytometry A 83:794–805
   Google Scholar